Zolgensma (onasemnogene abeparvovec) wasn't the first gene therapy approved in the U.S. That milestone belongs to Spark Therapeutics' Luxturna (voretigene neparvovec), a treatment for...
Hemophilia has become one of the most competitive battlegrounds in the emerging field of gene therapy. While BioMarin remains the frontrunner to market, a key...
Over more than three decades at the Food and Drug Administration, Janet Woodcock has seen the biotech industry mature from the early days of biologics...
Audentes Therapeutics is trying to show Sarepta isn't the only game in town when it comes to DMD. The collaboration with Nationwide's Children Hospital...
Wednesday's settlement follows last month's conviction of five former Insys executives, including the company's founder John Kapoor, for their involvement in bribing physicians to...
Biopharma companies wanting to treat rare diseases are increasingly pressed to be invested in gene therapy.
Novartis and Roche have recognized this with their...
Audentes Therapeutics is trying to show Sarepta isn't the only game in town when it comes to DMD. The collaboration with Nationwide's Children Hospital...
Biologics have been a business boon to contract manufacturers, Catalent included.
Large-molecule drugs are such a focus, in fact, that last year Catalent split its...
The plaques are considered hallmarks of Alzheimer's disease, formed in the brain from sticky clusters of a misfolded protein fragment called beta-amyloid.
For the past...
The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation focused...
Novo is best known for its insulin products like Levemir (insulin detemir) and Tresiba (insulin degludec), as well as other diabetes treatments like...
